Session: Communications on sarcoma and melanoma surgery by unknown
G Chir Vol. 34 - Suppl 1, 2013 - p. 115 
Supplement to n. 5/6, May-June 2013 abstracts
 
XXV National Congress of the “Società Polispecialistica Italiana dei Giovani Chirurghi” 
13-15 June 2013, Bari, Italy 
 
 
* Presenting Author 
 
© Copyright 2013, CIC Edizioni Internazionali, Roma    
 115 
PROGNOSTIC SIGNIFICANCE OF TYROSINASE EXPRESSION IN SENTINEL LYMPH NODE 
BIOPSY FOR ULTRA-THIN, THIN, AND THICK MELANOMAS 
 
A. CONVERSI*, E. CIGNA, D. RIBUFFO, N. SCUDERI 
 
Cattedra di Chirurgia Plastica, Ricostruttiva ed Estetica  "Sapienza" Università di Roma, Ospedale Policlinico Umberto I, 
"Sapienza" Università di Roma, Roma, Italia 
 
Objective: Investigate if the tyrosinase mRNA expression may be predictive of the outcome on ultra-thin, thin, and thick 
melanoma patients. In our study, we sought to correlate tyrosinase mRNA expression to the outcome in a group of 71 patients 
with thick, thin and ultra-thin melanomas. 
Methods: 71 patients with melanomas underwent a SLNB (sentinel lymph node biopsy) at the "Sapienza" University of 
Rome. Among these, 38 patients had thin melanomas, while the other 33 patients had thick melanomas. In every patient's 
sample histology, immunohistochemistry and reverse transcriptase-polymerase chain reaction (RT-PCR) was completed. We 
then correlated tyrosinase mRNA expression to the statistical analysis of the outcome of patients. 
Results: Positivity of histology was found in one patient (1.4%), immunohistochemistry in five patients (7%), and tyrosinase 
in 52/71 (73.2%). Thickness and tyrosinase positivity were predictive for disease progression (p < 0.05). The median follow-
up was 58.24 months. There were recurrences and/or deaths in both groups of patients. 
Conclusions: Nodal metastasis in melanoma is uncommon, especially in patients with thin melanomas. In this study, 
histology and immunohistochemistry were found to be non predictive for the risk of nodal metastases, while instead, 
tyrosinase m-RNA expression appeared to play a role in highlighting those patients with a risk of disease progression. 
Moreover, no differences among the thin melanoma groups of patients (0.30-0.75 mm and 0.76-1.00 mm) were observed. 
 
 
 
 
THE PROGNOSTIC VALUE OF THE NUMBER OF EXCISED LYMPH NODES IN RADICAL 
LYMPHADENECTOMY IN PATIENTS AFFECTED BY MELANOMA - ON BEHALF  
OF IMI (ITALIAN MELANOMA INTERGROUP) 
 
G. GIARDINELLI*, G. GIUDICE 
 
Università degli Studi di Bari "Aldo Moro", Azienda Ospedaliero-Universitaria Policlinico di Bari, Bari, Italia 
 
Objective: The aim of this study is to asses the effect of radical lymphadenectomy on the survival of patients affected by 
melanoma, to identify minimum number of lymph nodes that must be excised and  the patients who can benefit from this 
procedure. 
Methods: This study involved 2536 patients. 
Results: The number of lymph nodes excised during the radical limphadenectomy influence the survival of patients with 
lymph node metastases above all in presence of primitive tumors micrometastases with intermediate thickness and in patients 
who underwent a groin limphadenectomy. In underarm, groin and ileo-inguinal radical dissection, 12,9 and 11 limph nodes 
must be excised, respectively. 
Conclusions: The number of lymph nodes excised during the radical limphadenectomy can be considered a positive 
prognostic value. Further studies are needed to confirm these data and to investigate on radical dissection of the neck. 
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SENTINEL LYMPH NODE BIOPSY FOR CUTANEOUS MELANOMA IN DAY SURGERY 
 
E. RICCIARDI*, M. MONTUORI, F. DE SANCTIS, L. SANTURRO, A. FELIZIANI, D. GAUDIO, M.B. 
SILVI, P. ROSSI 
 
Department of Surgery, University Hospital of Tor Vergata, Rome, Italy 
Department of Dermatology, University Hospital of Tor Vergata, Rome, Italy 
Department of Pathological Anatomy, University Hospital of Tor Vergata, Rome, Italy 
 
Objective: The prognosis for melanoma depends primarily on primary tumor thickness and metastasis to regional lymph 
nodes. Several studies have demonstrated a sequential spread of lymph node metastasis. Staging with sentinel lymph mode 
biopsy (SLNB) has changed the diagnostic and therapeutic approach to melanoma and can obviate the need for prophylactic 
lymphadenectomy. With this study we evaluated the feasibility of SLNB as a day surgery procedure. 
Methods: A total of 158 Patients (88 males, 70 females) underwent SLNB for melanoma between February 2003 and January 
2013 at the Surgery Department of Tor Vergata University, Rome. The indication for SLNB was Breslow thickness >0.75, 
Clark >III and mitosis >1 high power field (HPF). After lymphoscintigraphy, were marked the points with the highest 
signal.Vital dye was never used. Intraoperative localization was obtained with a Scintiprobe MR-100. The kind of anesthesia 
depended on the number and site of the lymph nodes. 
Results: The preliminary lymphoscintigraphy clearly showed the site of lymph drainage. The sentinel lymph nodes were 
positive in 18 cases. The number of lymph nodes removed was <4 in 115 patients, 4-9 in 28, and >9 in 15. SLNB was 
performed in 60 hospitalized patients and as a day-surgery procedure in 78 patients. 
Conclusions: SLNB for cutaneous melanoma in day-surgery regimen is both safe and feasible. No patient in this series 
required hospitalization after the procedure. Using only radiotracers we consistently localized the sentinel lymph node. A 
multidisciplinary approach is mandatory in the diagnosis and treatment of melanoma. 
 
 
 
 
HEAD AND NECK MELANOMA: SENTINEL LYMPH NODE BIOPSY 
 
V. RONGHI*, S. LEUZZI, L. RAGUSA, G. GIUDICE, M. PASCONE 
 
Chirurgia Plastica, Ricostruttiva ed Estetica e Centro Ustioni, Policlinico di Bari, Università degli Studi di Bari, Bari, Italia 
 
Objective: The presence of melanoma in the head and neck has increased dramatically in the last decades. The widespread use 
of the sentinel lymph node biopsy in the management of head and neck melanoma has been limited though for several reasons: 
the complexity of lymphatic drainage in the head and neck region, the limited distance between the primary lesion and the 
sentinel node, the risk of a facial nerve injury, since approximately 25–30% of the sentinel nodes is found within the parotid 
gland.  
Methods: From 1999 we have treated 585 patients with melanoma. 15% of the patients examined had head and neck 
melanoma. Breslow > 1 mm  was found in 10% of the cases, therefore we opted for the search of the sentinel limph node. 
Results: Sentinel lymph nodes (SLNs) were successfully localized in more than 92% of cases. The rate of tumor-containing 
SLNs ranged from 15–20%. Only in these cases we performed latero-cervical limph nodes dissection. 
Conclusions: The sentinel node biopsy in melanoma of the head and neck region is currently the "gold standard" but the 
cooperation of experienced surgeons and nuclear medicine staff is essential for a successful procedure. These developments 
have significantly decreased the morbidity associated with the evaluation and treatment of the metastatic disease to the neck. 
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EDS PROTOCOL: SURGICAL TREATMENT OF BONE METASTASES IN THE APPENDICULAR 
SKELETON 
 
S. PELLE*, O. MORESCHINI, C. VILLANI 
 
Ortopedia e Traumatologia B, Università degli Studi di Roma "Sapienza", Roma, Italia 
Ortopedia e Traumatologia, Casa di Cura Villa Aurora, Roma, Italia 
 
Objective: Bone metastasis is the most common form of bone malignant tumor. More than 60% of all carcinoma tends to 
disseminate to skeleton which is the third site of metastatic spread after lung and liver. One of every five patients with 
metastatic neoplasm will have symptomatic bone metastases. 
Methods: The sites most commonly involved are the spine, pelvis and proximal extremity of long bones. The patient with 
metastatic bone disease is often treated by different specialists such as orthopaedic surgeons, oncologists, radiotherapists 
without any guideline. The Center EDS proposed a protocol for the treatment of appendicular skeleton metastases, which 
describes the indications for surgery, the types of operation and the available reconstruction techniques. 
Results: The protocol aim is to offer an individual treatment, in order to control pain and to manage impending and 
pathological fracture. In selected cases the complete resection of an isolated metastasis may be indicated. 
Conclusions: Short-term improvement in pain and in functional status is particularly important for patients with limited life 
expectancy. This is especially true for lesions involving the lower limb that severely restrict deambulation. Avoiding 
undertreatment or overtreatment, the orthopaedic surgery can improve so function as quality of life in patients with neoplastic 
diseases.    
 
 
 
 
SURGICAL MANAGEMENT OF ABDOMINAL MANIFESTATION OF TYPE 1 
NEUROFIBROMATOSIS: EXPERIENCE OF A SINGLE CENTER 
 
G. PEDULLÀ*, A. PALIOTTA, D. CROCETTI, A. DE GORI, M.R. TARALLO, G. CAVALLARO, G. DE 
TOMA 
 
Sapienza, Università di Roma, Policlinico Umberto I, Roma, Italia 
 
Objective: Neurofibromatosis type 1 (NF1) is a genetic disease characterized by neoplastic and nonneoplastic disorders 
involving tissues of neuroectodermal and mesenchymal origin. The mainly involved districts are skin, the central nervous 
system, and eye and there is a wide range of severity of clinical presentations. Abdominal manifestations of NF1 include five 
kinds of tumors: neurogenic tumors (neurofibromas, malignant peripheral nerve sheath tumors [MPNSTs], and 
ganglioneuromas); neuroendocrine tumors (pheochromocytomas and carcinoids); nonneurogenic gastrointestinal stromal 
tumors (GISTs); embryonal tumors; and miscellaneous.  
Methods and results: The present experience depends on the participation in the National Project for Diagnosis and 
Treatment of Rare Diseases. In the group of patients with a diagnosis of von Recklinghausen disease, 10 patients underwent 
surgical treatment for gastrointestinal and retroperitoneal tumors associated with NF1. Three patients underwent 
adrenalectomy for pheochromocytoma (in one case associated with jejunal wall neurofibroma); two patients were found to be 
affected by MPNST (recurrent and unresectable in one case). One patient was affected by giant gastric GIST and jejunal 
neurofibroma; two patients were affected by extraperitoneal neurofibroma (pararenal and pararectal position); one patient 
was affected by giant colic neurofibroma and one patient was affected by retroperitoneal bilateral plexiform neurofibromas.  
Conclusions: Early diagnosis of these abdominal manifestations is very important because of the risk of malignancy, organic 
complications (such as pheochromocytoma), or hemorrhagic-obstructivevcomplications such as in case of tumors of the 
gastrointestinal tract (GISTs and neurofibromas). The importance of an annual clinical evaluation on the part of a 
multidisciplinary pool of clinicians in highly specialized centers allows early detection of complications and of neoplastic 
transformation. Genetic screening allows preclinical diagnosis with a sensibility of 95 per cent. Further studies are necessary 
to detect predictive factors of malignant tumor development of severe clinical conditions. 
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ELECTROCHEMOTHERAPY, A NEW WEAPON AGAINST TUMORS. OUR EXPERIENCE IN THE 
HOSPITAL OF TOR VERGATA UNIVERSITY OF ROME 
 
M. MONTUORI, E. RICCIARDI*, F. DE SANCTIS, L. SANTURRO, A. FELIZIANI, D. GAUDIO,  
M.B. SILVI, P. ROSSI 
 
Università degli studi di Roma Tor Vergata, Policlinico Universitario Tor Vergata, Roma, Italia 
 
Objective: Electrochemotherapy (ECT) is a standardized treatment for cutaneous and subcutaneous tumors. The aim of this 
paper is to present our experience using ECT in cutaneous and subcutaneous tumors of different hystologies. 
Methods: As part of a multidisciplinary approach, using Cliniporator ® generator we treated 38 patients with 49 sessions: 2 
with local recurrence of squamous cell carcinoma of the anus, 1 with vulva’s carcinoma, 2 with metastatic soft tissue sarcoma, 
1 with cutaneous metastasis from neuroendocrine pancreatic carcinoma, 2 with cutaneous metastases from lung cancer, 4 with 
cutaneous metastatic melanoma, 4 with Kaposi's sarcoma, 4 with skin metastases from breast cancer and 15 with epitheliomas 
of the head and neck, 3 with epitheliomas of other districts. Our protocol follows European Standard Operating Procedures on 
Electrochemotherapy (ESOPE 2006). The main parameters evaluated were efficacy, bleeding and pain. The follow-up was 
performed by weekly outpatient visits until wound healing and photographic documentation. 
Results: We obtain excellent results regarding pain, bleedings, and the necrosis of the neoplastic tissue. We registered a good 
compliance of the procedure. In all cases there was a significant reduction of pain evaluated at 24h after treatment and patients 
referred an improvement of the quality of life. 
Conclusions: ECT is simple to perform and the results are independent tumor histology. It is also minimally invasive, and can 
be performed in Day Surgery with safety. This treatment is repeatable and requires a low chemotherapic dose and can be 
imbricated to standard chemotherapy treatments, with a high objective response rate. 
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